All-trans-retinoic acid nanodisks

Redmond, Katherine A.; Nguyen, Tinh; Ryan, Robert O.

doi:10.1016/j.ijpharm.2007.02.033

Cited by 56 publications

(42 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hwang and coworkers found that ATRA loaded in a phospholipid-based microemulsion provided similar growth inhibitory effects on HL-60 and MCF-7 cell lines to that free ATRA (12). The result is also in agreement with a previous study showing that ATRA incorporated into Nanodisks, disk-shaped phospholipid bilayers whose edge is stabilized by the association of apolipoprotein molecules, mediated time-dependent inhibition of cultured HepG2 cell growth more effectively than free ATRA (27). Cancers associated with defects in the retinoic acid pathway respond well to ATRA therapy.…”

Section: In Vitro Release Of Atra-loaded Nlcssupporting

confidence: 92%

Nanostructured Lipid Carriers (NLC) for Parenteral Delivery of an Anticancer Drug

et al. 2011

View full text Add to dashboard Cite

Abstract. The purpose of this research was to formulate nanostructured lipid carriers (NLC) for the parenteral delivery of an anticancer drug, all-trans retinoic acid (ATRA). The ATRA was incorporated into NLC by the de novo emulsification method. The effect of the formulation factor, i.e., type and oil ratio, initial ATRA concentration on physicochemical properties was determined. The anticancer efficacy of ATRA-loaded NLC on HL-60 and HepG2 cells was also studied. NLC was formulated using a blend of solid lipids (cetyl palmitate) and liquid lipids (soybean oil (S), medium-chain triglyceride (M), S/oleic acid (O; 3:1) and M/O (3:1)) at a weight ratio of 1:1. ATRA-loaded NLC had an average size of less than 200 nm (141.80 to 172.95 nm) with a narrow PDI and negative zeta potential that was within an acceptable range for intravenous injection. The results indicated that oleic acid enhanced the ATRAloading capacity of NLC. In vitro ATRA release was only approximately 4.06% to 4.34% for 48 h, and no significant difference in ATRA release rate from all NLC formulations in accordance with the composition of the oil phase. Moreover, no burst release of the drug was observed, indicating that NLC could prolong the release of ATRA. The initial drug concentration affected the photodegradation rate but did not affect the release rate. All ATRA-loaded NLC formulations exhibited the photoprotective property. The cytotoxicity results showed that all ATRA-loaded NLC had higher cytotoxicity than the free drug and HL-60 cells were more sensitive to ATRA than HepG2 cells.

show abstract

Section: In Vitro Release Of Atra-loaded Nlcssupporting

confidence: 92%

Nanostructured Lipid Carriers (NLC) for Parenteral Delivery of an Anticancer Drug

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Ryan et al (7,8) synthesized nanodisk (ND) particles comprised of a disk-shaped phospholipid bilayer. The perimeter of the bilayer is stabilized by apoplipoprotein A1 molecules.…”

Section: Nanodisks -Drug Delivery Nanoparticle Vehiclesmentioning

confidence: 99%

“…This water insoluble bioactive lipid was stably incorporated into nanoscale lipid particles -the NDs (15,16). We hypothesized that, following cellular uptake and/or liberation of ATRA from ND, this retinoid would interact with intracellular binding proteins and, ultimately, nuclear hormone receptors, leading to target gene transactivation, cell growth arrest and/or apoptosis.…”

Section: Nanodisks -Drug Delivery Nanoparticle Vehiclesmentioning

confidence: 99%

Update on Nanotechnology-based Drug Delivery Systems in Cancer Treatment

Pfeffer

Singh

2017

View full text Add to dashboard Cite

Abstract. The Cancer is the second leading cause of death, following heart diseases (1), killing approximately eight million people (600,000 per year) and affecting nearly fourteen million (2).The rate at which cancer is emerging is only increasing as time goes on due to such factors as increased pollution, radiation, lack of exercise and a balanced diet, among other variables such as genetics (3). Anyone of these factors can lead to a mutation in the DNA of our cells like oncogenes and develop into cancer. The immortalization and sustainability of individual cells capable of reproducing at astonishing rates, overtake all the healthy functional cells, and eventually lead to death.The most common types of treatment against cancer include chemotherapy, surgery, radiation, and a combination of any of these treatments. However, there are challenges associated with the traditional treatments -non-specificity, toxicity, etc. The challenge of current drug therapy is the optimization of the pharmacological action of the drug, and the minimization of its toxic side effect. Local concentration of the drug at the cancer sites needs to be high, while at other tissues low to prevent any negative reactions. Application of nanotechnology in cancer treatment has the potential to solve these limitations. Designing nanoparticles loaded with multifunctional drugs, and functionalizing their surfaces with recognition proteins can target specific cancer cells (4, 5). The advantages of such targeting include the drug amount needed to achieve a therapeutic effect may be significantly reduced as well as the drug concentration on the cancer site can be increased without any bad effects on healthy cells (6).Several nanoparticle based drug delivery systemsnanodisks, HDL nanostructures, gold nanoparticles, and viral nanoparticles -have shown encouraging results in cancer therapy. Progress has been made in studying the biological features of cancer to enhance the use of nanoparticlesovercoming biological barriers, and recognizing cancerous tissue vs. healthy tissue. Looking forward, nanodrugs have great potential in cancer therapy due to their unique properties -minimizing toxicity to healthy cells, overcoming multidrug resistance (MDR), and overcoming poor solubility of anti-cancer drugs. 5975

show abstract

“…[21][22][23][24] After equal moles of paclitaxel and POPC were mixed together in the presence of 100 mM sodium cholate, the detergent was removed either by dilution or dialysis and apolipoprotein A-I was added at the time of dilution or dialysis. After removing protein and paclitaxel precipitates by centrifugation, the supernatant was subjected to separation by size exclusion chromatography.…”

Section: Assembly Of Paclitaxel Nanoparticlesmentioning

confidence: 99%

pH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy

Shin

Yang²,

Heo³

et al. 2012

IJN

View full text Add to dashboard Cite

Background: Nanoparticles undergoing physicochemical changes to release enclosed drugs at acidic pH conditions are promising vehicles for antitumor drug delivery. Among the various drug carriers, high-density lipoprotein (HDL)-like nanoparticles have been shown to be beneficial for cancer chemotherapy, but have not yet been designed to be pH-responsive. Methods and results:In this study, we developed a pH-responsive HDL-like nanoparticle that selectively releases paclitaxel, a model antitumor drug, at acidic pH. While the well known HDL-like nanoparticle containing phospholipids, phosphatidylcholine, and apolipoprotein A-I, as well as paclitaxel (PTX-PL-NP) was structurally robust at a wide range of pH values (3.8-10.0), the paclitaxel nanoparticle that only contained paclitaxel and apoA-I selectively released paclitaxel into the medium at low pH. The paclitaxel nanoparticle was stable at physiological and basic pH values, and over a wide range of temperatures, which is a required feature for efficient cancer chemotherapy. The homogeneous assembly enabled high paclitaxel loading per nanoparticle, which was 62.2% (w/w). The molar ratio of apolipoprotein A-I and paclitaxel was 1:55, suggesting that a single nanoparticle contained approximately 110 paclitaxel particles in a spherical structure with a 9.2 nm diameter. Among the several reconstitution methods applied, simple dilution following sonication enhanced the reconstitution yield of soluble paclitaxel nanoparticles, which was 0.66. As a result of the pH responsiveness, the anticancer effect of paclitaxel nanoparticles was much more potent than free paclitaxel or PTX-PL-NP. Conclusion: The anticancer efficacy of both paclitaxel nanoparticles and PTX-PL-NP was dependent on the expression of scavenger receptor class B type I, while the killing efficacy of free paclitaxel was independent of this receptor. We speculate that the pH responsiveness of paclitaxel nanoparticles enabled efficient endosomal escape of paclitaxel before lysosomal break down. This is the first report on pH-responsive nanoparticles that do not contain any synthetic polymer.

show abstract

All-trans-retinoic acid nanodisks

Cited by 56 publications

References 28 publications

Nanostructured Lipid Carriers (NLC) for Parenteral Delivery of an Anticancer Drug

Nanostructured Lipid Carriers (NLC) for Parenteral Delivery of an Anticancer Drug

Update on Nanotechnology-based Drug Delivery Systems in Cancer Treatment

pH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy

Contact Info

Product

Resources

About